Publish time: 2022-08-17 00:00:00
10A-1110530
Patent Pending
We used the mRNA-lipid nanoparticle immunization method to generate a set of Omicron-targeting monoclonal antibodies. Five of our novel K-RBD-mAbs show strong binding and neutralizing activities toward all WHO-issued SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron). Notably, the epitopes of these five K-RBD-mAbs are overlapping and localized around K417 and F486 of receptor binding domain (RBD) in the spike protein. Chimeric derivatives of the five antibodies (K-RBD-chAbs) neutralize Omicron sublineages BA.1 and BA.2 with low IC50 values that range from 5.7 to 12.9 ng/mL. Additionally, we performed antibody humanization on broadly neutralizing chimeric antibodies to create K-RBD-hAb-60 and K-RBD-hAb-62, which still retain excellent neutralizing activity against Omicron. Our results collectively suggest that these five therapeutic antibodies may effectively combat a variety of SARS-CoV-2 variants, including Omicron BA.1 and BA.2.
- Humanized antibodies have high specificity, low immune rejection and few side effects.
- The antibodies of this invention can broadly neutralize a variety of SARS-CoV-2 variants including Alpha, Beta, Kappa, Gamma, Delta and Omicron.
- The antibodies of this invention have high neutralizing activity to SARS-CoV-2 Omicron BA.1 and BA.2.
Development of therapeutic antibody drugs for COVID-19
Han-Chung Wu, Ruei-Min Lu, Wan-Yu Chen and Hsiu-Ting Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice